Download PDF
Thromb Haemost 1963; 09(01): 074-089
DOI: 10.1055/s-0038-1654962
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Behaviour of Factors II, VII, IX, and X during Long-Term Treatment with Coumarin

E. A Loeliger
1   Department of Haematology of the Clinic for Internal Medicine (Director: Prof. Dr. ]. Mulder), University Hospital, and the Thrombosis Service (Head: Dr. E.A. Loeliger), Leyden, The Netherlands
,
B van der Esch
1   Department of Haematology of the Clinic for Internal Medicine (Director: Prof. Dr. ]. Mulder), University Hospital, and the Thrombosis Service (Head: Dr. E.A. Loeliger), Leyden, The Netherlands
,
M. J Mattern
1   Department of Haematology of the Clinic for Internal Medicine (Director: Prof. Dr. ]. Mulder), University Hospital, and the Thrombosis Service (Head: Dr. E.A. Loeliger), Leyden, The Netherlands
,
A. S. A den Brabander
1   Department of Haematology of the Clinic for Internal Medicine (Director: Prof. Dr. ]. Mulder), University Hospital, and the Thrombosis Service (Head: Dr. E.A. Loeliger), Leyden, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

    Permissions and Reprints

Summary

During long-term treatment with the long-acting coumarin derivative phenprocoumarol (marcoumar) no statistically significant difference in the depression of the activity of coagulation factors II, VII, IX, and X was found. The shorter-acting anticoagulants acenocoumarol (sintrom), warfarin sodium (coumadin), and dicoumarol, possibly lower factor IX somewhat less and factor X somewhat more than they do factors II and VII.

A 2.5-fold prolongation of the “prothrombin” time (using Owren 5 s human brain thromboplastin) and the same prolongation of the thrombotest time appear to correspond with a depression of all four factors from 100% down to approximately 20’%, the normal standard being a mixed population with a mean age of 29 years.

Separate determination of one of the four coagulation factors concerned is pointless; “prothrombin” time estimation, and more specifically thrombotest, still remain the most reliable methods for controlling the anti-vitamin K action of anticoagulants during long-term treatment.

 

  • References

  • 1 Bachmann F, Duckert F, Koller F. The Stuart-Prower factor assay and its clinical significance. Thrombos. Diathes. haemorrh. 02: 24 1958;
    PubMedGoogle Scholar
  • 2 Bell W. N, Alton H. G. Brain extracts as a substitute for platelet suspensions in the thromboplastin generation-test. Nature (Lond) 174: 880 1954;
    CrossrefPubMedGoogle Scholar
  • 3 Biggs R, Bidwell E, Handley D. A, Macfarlane R. G, Trueta J, Elliot-Smith A, Dike G. W. R, Ash B. J. The preparation and assay of a Christmas-factor (factor IX) concentrate and its use in the treatment of two patients. Brit. J. Haemat. 07: 349 1961;
    CrossrefPubMedGoogle Scholar
  • 4 Esch van der B. Thesis, Leiden (to be published.
    PubMedGoogle Scholar
  • 5 Folch J. Brain cephalin, a mixture of phosphatides. Separation from it of a phosphatidyl serine, phosphatidyl ethanolamine, and a fraction containing an inositol phosphatide. J. biol. Chem. 146: 35 1942;
    PubMedGoogle Scholar
  • 6 Hicks N. D, Bonnin J. A. The behaviour of coagulation factors during anticoagulant therapy with special reference to the one-stage test as an index of therapy. Brit. J. Haemat. 05: 194 1959;
    CrossrefPubMedGoogle Scholar
  • 7 Johnson S. A, Caldwell M. J, Priest EMcCall. Effect of oral anticoagulant (marcoumar) on prothrombin and related components in blood coagulation. Circulation Res. 05: 252 1957;
    CrossrefPubMedGoogle Scholar
  • 8 Koller F. Antikoagulantien bei Herzkrankheiten. Schweiz, med. Wschr. 92: 769 1962;
    PubMedGoogle Scholar
  • 9 Loeliger E. A. Über den Nachweis eines neuen Blutgerinnungsfaktors: Faktor VII. Thesis, Zürich 1952. Wien. Z. inn. Med. 03: 169 1952;
    PubMedGoogle Scholar
  • 10 Loeliger E. A. Probleme der Antikoagulantienbehandlung in der Inneren Medizin. III. Hamburger Symposion über Blutgerinnung. Thrombos. Diathes. haemoorh. 05 (Suppl.) 46 1961;
    PubMedGoogle Scholar
  • 11 Loeliger E. A, Hensen A. Substitution therapy in haemophilia B. Thrombos. Diathes. haemorrh. 06: 391 1961;
    PubMedGoogle Scholar
  • 12 Loeliger E. A, van der Esch B, Mattern M. J. The turnover rate of prothrombin, factor VII and factor X in hypo-and hyperthyroidism and during fever (to be published.
    PubMedGoogle Scholar
  • 13 Owren P. A, Aas K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest 03: 169 1951;
    CrossrefPubMedGoogle Scholar
  • 14 Owren P. A. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 02: 754 1959;
    PubMedGoogle Scholar
  • 15 Owren P. A. Critical study of tests for control of anticoagulant therapy. In: Wright I. S, Koller F, Beck E. Progress in coagulation. Thrombos. Diathes. haemorrh. 7 (Suppl.) 294 1962
    Google Scholar
  • 16 Shanberge J. N. The effect of dicoumarol on certain factors of blood coagulation. J. Lab. clin. Med. 48: 218 1956;
    PubMedGoogle Scholar
  • 17 Vermeulen H. J, ten Huinink S. ABokkel, Radhakishun K. S. Some observations on the coagulation defect during treatment with the anticoagulant “Sintrom”. Thrombos. Diathes. haemorrh. 03: 92 1959;
    PubMedGoogle Scholar
  • 18 Walker W. Control of anticoagulant therapy: critical evaluation of control methods. In: Wright I. S, Koller F, Beck E. Progress in coagulation. Thrombos. Diathes. haemorrh. 7 (Suppl. 284) 1962
    Google Scholar
  • 19 Zollikofer H, Schulthess P. v, Pugatsch I. Über eine neue Kontroll-methode der Antikoagulantientherapie. Helv. med. Acta. 25: 465 1958;
    PubMedGoogle Scholar